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Biochemistry; University of Cambridge; Cambridge, UK; 6Institute for Molecular Medicine Finland (FIMM); University of Helsinki; Helsinki, Finland; 7Foundation for the Finnish
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Abbreviations: Cdk6, cyclin dependent kinase 6; GSI, g-secretase inhibitor; KS, Kaposi’s sarcoma; KSHV, Kaposi’s sarcoma
herpesvirus; NICD1, Notch1 intracellular domain; NICD3, Notch3 intracellular domain; PEL, primary effusion lymphoma
PI, propidium iodide; v-cyclin, viral cyclin.
Kaposi’s sarcoma herpesvirus (KSHV)-encoded v-cyclin, a homolog of cellular cyclin D2, activates cellular CDK6,
promotes G1-S transition of the cell cycle, induces DNA damage, apoptosis, autophagy and is reported to have
oncogenic potential. Here we show that in vivo expression of v-cyclin in the B- and T-cell lymphocyte compartments
results in a markedly low survival due to high penetrance of early-onset T-cell lymphoma and pancarditis. The v-cyclin
transgenic mice have smaller pre-tumorigenic lymphoid organs, showing decreased cellularity, and increased proliferation
and apoptosis. Furthermore, v-cyclin expression resulted in decreased amounts of CD3-expressing mature T-cells in the
secondary lymphoid organs concurrent with alterations in the T-cell subpopulations of the thymus. This suggests that
v-cyclin interferes with normal T-cell development. As the Notch pathway is recognized for its role in both T-cell
development and lymphoma initiation, we addressed the role of Notch in the v-cyclin-induced alterations. Fittingly, we
demonstrate induction of Notch3 and Hes1 in the pre-tumorigenic thymi and lymphomas of v-cyclin expressing mice, and
show that lymphoma growth and viability are dependent on activated Notch signaling. Notch3 transcription and growth
of the lymphomas was dependent on CDK6, as determined by silencing of CDK6 expression or chemical inhibition,
respectively. Our work here reveals a viral cyclin-CDK6 complex as an upstream regulator of Notch receptor, suggesting
that cyclins can play a role in the initiation of Notch-dependent lymphomagenesis.
Introduction
Kaposi`s sarcoma herpesvirus (KSHV) belongs to the family of
lymphotropic gammaherpesviruses and is an etiologic agent of 3
malignancies, namely Kaposi`s sarcoma (KS), primary effusion
lymphoma (PEL) and some forms of multicentric Castleman`s
Disease (MCD).1-3 PELs are lymphomas with unique clinical,
morphologic, and immunophenotypic features. They appear as
pleural, pericardial or peritoneal effusions,4 and show aggressive
behavior with a median survival of only 6 months after diagnosis.5
Although the majority of PELs exhibit an indeterminate (non B-
non T-cell) immunophenotype, immunogenotypic studies have
demonstrated both immunoblastic and plasma cell features defin-
ing a B-cell origin.6 However, rare KSHV-associated T-cell lym-
phomas have also been documented, and PELs with an aberrant
T-cell genotype or phenotype have been characterized.7-9 CD138,
also called syndecan-1 (Sdc1), is a marker of plasma cells and con-
sidered a specific marker for KSHV-associated primary effusion
lymphomas (PEL),10,11 and at least part of the KSHV-associated
T-cell lymphomas have been shown to express it.7
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Abnormal Notch signaling is associated with KSHV-induced
malignancies,12 and KS tumors overexpress several Notch path-
way components, including the ligands, Notch receptors and the
target genes Hes-1 and Hey-1.13,14 Moreover, Liu et al. have
shown that exogenous expression of a plethora of KSHV encoded
genes, namely LANA, vFLIP, RTA, vGPCR and vIL6 can induce
expression of the Notch pathway components in HEK293T
cells.14 Activation of the Notch ligands Jagged1 and Dll4 by viral
proteins vFLIP and vGPCR, has also been demonstrated in an
endothelial cell model.15 In addition, KSHV latency protein
LANA-dependent accumulation of the active Notch1 intracellu-
lar domain (NICD1) in PEL cells was shown to result in
increased proliferation.16,17 Furthermore, primary KS tumor cells
and experimental lesions in mice were sensitive to inhibition of
Notch signaling by g-secretase inhibitors (GSIs),13,18 which
block the proteolytic processing of the full-length Notch receptor
to NICD. GSI treatment of the KSHV-infected PEL cell lines
leads to G1 cell cycle arrest in vitro16 and induces cell death in
PEL xenografts in mice.19 These data suggest that inhibition of
activated Notch signaling could have therapeutic potential for
both KS tumors and KSHV-induced PELs.
KSHV encodes a viral cyclin (v-cyclin, v-cyc), which is a cellular
cyclin D2 homolog and associates with cellular cyclin dependent
kinase 6 (CDK6).20 v-cyclin is expressed both during KSHV
latency and lytic replication phase. Binding of v-cyclin activates
CDK6 to phosphorylate the retinoblastoma protein (pRb)21 lead-
ing to accelerated S-phase entry in cultured cells.22 Besides pRb, the
v-cyclin-CDK6 complex phosphorylates a plethora of other sub-
strates. These include substrates normally phosphorylated by the S-
phase cyclin E-CDK2 complex including histone H1, CDC6,
ORC123-25 and Bcl-2.26 v-cyclin-CDK6 is insensitive to several cell
cycle control mechanisms, thus deregulating the cell cycle. Evasion
of the cell cycle control is at least partially attributed to the capacity
of v-cyclin-CDK6 to phosphorylate and thereby inactivate the
CDK inhibitors p27Kip1 and p21Cip1.23,25,27-29 In addition, v-
cyclin has recently been shown to promote KSHV-induced post-
confluent growth and transformation in rat mesenchymal cells,30
and to counteract the G1-arrest triggered by another latent viral
protein, vFLIP, through NF-kB hyperactivation.31 However, v-
cyclin not only promotes proliferation, as its overexpression also
induces a p53-dependent growth arrest and apoptosis,26,32-34 acti-
vates the DNA damage response,32 and increases autophagy.35
The in vivo function of v-cyclin in the lymphocyte compart-
ment has previously been addressed by expressing it as a transgene
under the immunoglobulin heavy chain promoter/enhancer Em
in a mixed CBA/C57BL/6 mouse background (Em-v-cyclin
mice).33,36 Expression of v-cyclin led to development of low pene-
trance (17%), late onset lymphomas, which was accelerated by
p53 deficiency. Considering the multiple functions that have been
assigned to v-cyclin in the in vitro cell culture studies,22 the mild
oncogenic phenotype in the Em-v-cyclin mice was quite surpris-
ing.33,36 As the C57BL/6 background used in these studies is con-
sidered to be refractory to at least chemically induced tumors,37
we crossbred the Em-v-cyclin mice from the mixed C57BL/6
background into ICR (CD1) and assessed the tumorigenic
potential of v-cyclin in these mice. Our results show that v-cyclin
expression in the ICR (CD1) mouse background leads to abnor-
mal T-cell differentiation as well as early onset T-cell lymphomas
in a vast majority of the animals. Furthermore, we show that v-
cyclin induces Notch3 receptor expression in mouse pre-tumori-
genic thymocytes, and that v-cyclin initiated T-cell lymphomas
are dependent on both Cdk4/6 and Notch pathway activities.
Results
v-cyclin expression in thymocytes leads to high penetrance
T-cell lymphomagenesis and pancarditis
Em-v-cyclin mice, initially generated in a mixed CBA/C57BL/
6 mouse background33,36 were bred to the ICR (CD1) genetic
background. The Kaplan-Meier analysis of the v-cyclin express-
ing ICR mice (ICR v-cyclin) revealed low survival (less than 5%)
and early-onset disease starting at 1.5 months of age, while the
disease-free survival of the non-transgenic ICR littermates
(ICR wt) remained 100% during the follow-up period (Fig. 1A).
As this dramatically differed from the reported 83% survival of
the CBA/C57BL/6-Em-v-cyclin mice,33,36 we ruled out the pos-
sibility of mutations in the major tumor suppressors p53 or
p19Arf by sequencing. The 10 Trp53 and 2 Cdkn2a exons con-
taining most of the hot spot mutations38 were devoid of muta-
tions in the ICR mice (data not shown). Moreover, when the
ICR-Em-v-cyclin mice were backcrossed with C57BL/6 mice to
generate C57BL/6-Em-v-cyclin mice (BL6 v-cyclin), the v-
cyclin-associated disease phenotype was reverted to that observed
in the original mixed background (Fig. S1A), suggesting that the
decreased survival in v-cyclin mice was dependent on the ICR
background. A comparison of the expression levels of v-cyclin in
thymi of 5-week old mice in the 2 different backgrounds showed
that v-cyclin expression was 2.5 to three-fold higher in ICR mice
(Fig. S1B), which could partially contribute to the phenotype in
ICR-Em-v-cyclin mice.
Examination of ICR-Em-v-cyclin mice by necropsy (n D 27)
and histology (n D 13) showed that 74% of the diseased animals
displayed signs of lymphoma (Fig. 1B), mostly in the thymus
and spleen (85% and 65% of lymphoma-bearing animals, respec-
tively). The lymphomas showed diffuse proliferation of monoto-
nous, intermediate sized lymphoid cells with numerous scattered
tingible body macrophages (arrows) and mitotic figures (arrow-
heads) (Fig. 1B, panels i and ii). Neoplastic lymphoid cells
showed round to slightly irregular nuclei with finely clumped,
dispersed chromatin and multiple basophilic nucleoli. In about a
third of the lymphoma-bearing mice, the lymphoma had spread
to liver and lungs, with tumor cells appearing around blood ves-
sels or sinusoids in the liver and in perivascular and peribronchio-
lar spaces in the lung (Fig. 1B, panels iii and iv). Tumor cells
were occasionally detected in lymph nodes. All lymphomas
examined by immunohistochemistry, IHC, (10/10) were com-
posed of lymphomatous T-cells cells positive for CD3, a pan-T-
cell marker recognizing the components of the TCR complex,
and were negative for the B-cell marker B220 (Fig. 1C).
We next established 6 cell lines from primary lymphomas iso-
lated from different organs of 3 tumor-bearing animals. FACS
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Figure 1. v-cyclin expression leads to T-cell lymphomas and pancardial inﬂammation. (A) Kaplan-Meyer survival charts of v-cyclin expressing (Em-v-cyclin,
n D 40) and littermate control animals (wt, n D 28) in the ICR (CD1) mouse background. (B) Hematoxylin and eosin (H&E) stained sections of Em-v-cyclin
lymphomas in i) thymus (low magniﬁcation), ii) thymus (high magniﬁcation), iii) liver, and iv) lung. (C) Immunohistochemistry of a representative Em-v-
cyclin thymus lymphoma with antibodies against CD3 and B220. (D) FACS analysis of Em-v-cyclin lymphoma cell lines isolated from 3 lymphoma-bearing
mice (v-cyc1, v-cyc2, v-cyc3) with the indicated combinations of antibodies against CD4 and CD8. T D thymus, S D spleen, LN D lymph node. (E) mRNA
expression levels of CD138 in the cell lines in (D) compared and normalized to wt control thymus (n D 2). A thymic lymphoma cell line from an Em-Myc
mouse (Em-Myc) was used as a control. (F) Sections of a representative Em-v-cyclin heart affected with pancarditis and stained with i) and ii) H&E, low
and high magniﬁcation, respectively; and antibodies against iii) CD3 and iv) B220. Magniﬁcations in (B); i, iii, iv: x10, ii: x40; in (C): x10 (insert x50). Scale
bars in (F): i: 400 mm; ii, iii, and iv: 50 mm. Error bars in (E): s.e.m., n D 2. p-values: *P < 0.05, **P < 0.01, ***P < 0.001.
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analysis indicated variation in the CD4/CD8 status of the thymic
lymphomas, with 2 of the animals containing tumors composed
of mostly immature CD4/CD8 double negative (DN) T-cells
(Fig. 1D), and the third consisting primarily of CD4/CD8 dou-
ble positive (DP) cells (Fig. 1D). These immunophenotypes indi-
cate an early T-cell stage and together with the histological blastic
appearance, are consistent with a classification as lymphoblastic
T-cell lymphomas. As also the rare KSHV-associated T-cell lym-
phomas have been shown to express the plasma cell marker
CD138, we next analyzed the expression of CD138 mRNA in v-
cyclin mouse lymphomas by qRT-PCR. Intriguingly, all thymic
v-cyclin lymphoma cell lines showed a 10-fold higher expression
of CD138 when compared to wt control thymus (Fig. 1E). Con-
trol lymphoma cells isolated from Em-Myc thymic lymphoma
showed no expression of CD138 (Fig. 1E). This suggests that v-
cyclin-induced lymphoma cells express markers of both imma-
ture T-cells, as well as plasma/PEL cells.
We noticed during follow-up that a large proportion (52%) of
v-cyclin-expressing animals showed signs of insufficient heart
function at young age (1–6 months). At necropsy, pancarditis
was detected in all of these animals, with around half of them dis-
playing no detectable lymphoma (Fig. 1F). The inflammation
suffused extensive areas of the hearts (Fig. 1F, panels i and ii,
H&E stainings) and, in all animals examined by IHC (6/6), pri-
marily consisted of CD3-positive T-cells (Fig. 1F, panel iii,
examples of the CD3-positive cells are pointed by arrows) with
occasional involvement of B220-positive B-cells (Fig. 1F, panel
iv, examples of the B220-positive cells are pointed by arrows). As
this inflammatory state contributed to the poor survival of the
ICR-Em-v-cyclin mice, and the T-cells were detected also in
hearts of animals with no tumors, the data indicates that T-cell
escape from the thymus or spleen is an early event and suggests
that both T-cell function and immune system may be severely
compromised in these animals.
v-cyclin is expressed and activates its kinase partner Cdk6
in vivo
We next analyzed expression of the transgene and observed
that v-cyclin mRNA was expressed at almost 700-fold lower level
in the pre-tumorigenic thymus than in the spleen leading to a
markedly reduced protein expression (Fig. 2A and S2A). To
assess if the lymphoma cells retained v-cyclin expression, we com-
pared v-cyclin expression levels to those of pre-tumorigenic thymi
and spleens by qRT-PCR. The transcripts of v-cyclin remained at
similar low levels in the thymi and the thymic lymphomas, and
were 50-fold further decreased in the thymic Em-v-cyclin lym-
phoma cell lines (Fig. 2B left panel). The splenic lymphomas
exhibited significantly lower v-cyclin mRNA and protein expres-
sion levels than the pre-tumorigenic spleens, probably reflecting
the changes in the cellular composition toward a higher T-cell
fraction, which is in accordance with the elevated CD3 expres-
sion in the splenic lymphomas (Fig. 2B right panel and 2C). The
splenic Em-v-cyclin lymphoma cell lines showed similar low v-
cyclin expression levels as the thymic lymphoma cell lines
(Fig. 2B right panel). No v-cyclin mRNA was detected in the
control wt mice or Em-Myc cell line (data not shown).
As the numerous in vitro studies have shown that v-cyclin
mediates its known functions through activation of CDK6,22 we
next analyzed the levels of Cdk6 from pre-tumorigenic organs
and v-cyclin lymphomas. In accordance with our recent study
demonstrating NF-kB activation by v-cyclin-Cdk6,39 2.3-fold
higher Cdk6 protein levels were detected in the v-cyclin express-
ing thymi when compared to the littermate controls (Fig. S2A).
Stabilization of Cdk6 by 1.7-fold was also observed in the pre-
tumorigenic spleens (Fig. 2C and S2A-B) and especially clearly
in splenic lymphomas (Fig. 2C). Cdk6 was expressed at higher
levels in the thymi than in the spleens irrespective of the v-cyclin
transgene expression (Fig. S2A). This suggests that although v-
cyclin is expressed at low levels in the thymus, it is possible that
the v-cyclin mediated Cdk6 stabilization contributes to the stron-
ger phenotypes observed in the thymus than spleen.
To confirm that the expressed v-cyclin was functional and
capable to activate Cdk6 in our transgenic model, we isolated
splenocytes from the Em-v-cyclin and control mice, and first
individually immunodepleted Cdk2, Cdk4, or Cdk6 from the
cell extracts (Fig. 2D). Efficient immunodepletion of the individ-
ual Cdks was confirmed by immunoblotting with Cdk2, Cdk4
and Cdk6 antibodies (Fig. S2B). We then immunoprecipitated
v-cyclin from the Cdk-depleted and control extracts and sub-
jected the immunoprecipitates (IPs) to an in vitro kinase assay
using GST-Rb and Histone H1 as substrates. Phosphorylation of
both substrates was evident in the IPs of Em-v-cyclin splenocytes,
whereas only a weak background signal could be detected in the
long exposure of the filter when IPs were performed from wild
type (wt) splenocytes (Fig. 2D, data from one representative
mouse of each genotype is shown, n D 3). However, depletion of
Cdk6 or Cdk4, but not Cdk2, from the Em-v-cyclin splenocyte
extracts resulted in a 2.5 to 3-fold decrease in both v-cyclin levels
(detected by its FLAG-tag) and diminished phosphorylation of
GST-Rb and Histone H1 by 50% and 80–99%, respectively
(Fig. 2D). As Cdk4 immunodepletion also reduced the levels of
Cdk6 (50% depleted, Fig. S2B), it is possible that the detected
reduction in v-cyclin levels and kinase activity in the Cdk4
depleted samples is actually due to the co-depletion of Cdk6
rather than specific v-cyclin-dependent Cdk4 activity.
v-cyclin-induced lymphomas are dependent on the
Cdk4/6 activity
To address if the activity of v-cyclin cellular kinase partner
Cdk6 was necessary for the growth of the Em-v-cyclin lymphoma
cells, lymphoma cell lines isolated from 3 Em-v-cyclin and one
control Em-Myc mice were treated with a Cdk4/6 kinase inhibi-
tor PD0332991 (PD). The efficacy of PD treatment was first
demonstrated by a 10-fold reduction in cyclin A protein levels
after treatment (Fig. S3A), indicating a G1 arrest in the cell cycle
due to Cdk4/6 inhibition. Interestingly, PD treatment resulted
in a growth arrest in all Em-v-cyclin derived lymphoma lines
examined (see one representative example in Fig. 3A). To investi-
gate if the PD treatment compromised the viability of the lym-
phoma cells, we determined the number of dead cells by trypan
blue exclusion. The low concentration PD treatment induced sig-
nificant cell death in all Em-v-cyclin lymphomas, as there was a
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Figure 2. v-cyclin transgene is expressed and functional in the splenocytes isolated from the Em-v-cyclin mice. qRT-PCR analysis of v-cyclin mRNA expres-
sion (A) in 5-week old Em-v-cyclin mouse pretumorigenic thymi (n D 4) and spleens (n D 3), and normalized to the thymus expression levels set to one
and (B) in thymic and splenic lymphomas (n D 3 and n D 4, respectively) compared and normalized to the respective pre-tumorigenic organs of 5-week
old mice (thymus n D 4, spleen n D 3). (C) Protein levels of FLAG-v-cyclin, Cdk6 and CD3 were analyzed by immunoblotting of total cell lysates prepared
from isolated splenocytes of Em-v-cyclin (v-cyc), control mice (wt), and cells isolated from v-cyclin splenic lymphomas. g-tubulin served as a loading con-
trol. (D) In vitro kinase assay using GST-Rb and Histone H1 as substrates. Prior to the kinase reaction, isolated splenocytes from Em-v-cyclin (v-cyc TG; C)
and control mice (¡) were immunodepleted with antibodies against Cdk2, Cdk4, and Cdk6 followed by immunoprecipitation of v-cyclin by anti-FLAG
antibodies. Kinase activity was determined by autoradiography after SDS-PAGE (12%) followed by immunoblotting with antibodies against FLAG. Total
cell extracts showing the input served as controls for the immunoprecipitated proteins. Error bars in (A), (B): s.e.m. p-values: *P < 0.05, **P < 0.01,
***P < 0.001.
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10–50% increase in cell death after 48 hours of treatment
(Fig. 3B). In contrast, PD had no effect on cell viability of the
Em-Myc derived, v-cyclin negative control lymphoma (2.5% cell
death; Fig. 3B), suggesting that Cdk6 activity is required for the
growth and survival of v-cyclin-induced lymphomas.
As v-cyclin has been shown to bind and activate CDK6 also in
patient-derived KSHV-infected BCBL-1 PEL cells,40 we next
tested the effect of PD treatment on the growth and viability of
BCBL-1 cells. Confirming its efficacy on the v-cyclin-dependent
kinase activity, PD treatment led to a 50–90% (with 0.5 mM
and 1 mM concentrations of PD, respectively) reduction in phos-
phorylation of a known v-cyclin-CDK6 substrate, pT199NPM
(nucleophosmin)41 (Fig. S3B) as well as a marked reduction in
cyclin A levels (Fig. S3B). Importantly, the inhibitor treatment
of BCBL-1 cells led to a growth arrest (Fig. 3C) and a dose-
dependent induction of relative cell death by 7% and 22%
(0.5 mM and 1 mM, respectively) (Fig. 3D) when compared to
the vehicle control. These
results demonstrate that
both the
v-cyclin-expressing mouse
lymphoma cells and the
patient-derived lymphoma
cells are sensitive to
CDK4/6 inhibition.
v-cyclin induces
increased proliferation/
apoptosis and an intra-S-
phase block in pre-
tumorigenic lymphoid
organs
We next sought to
investigate the effect of v-
cyclin expression in the
lymphocyte compartment
prior to the onset of lym-
phomas. Macroscopic anal-
ysis of the lymphoid organs
revealed that v-cyclin
expressing animals had
markedly smaller thymi,
and a slight decrease in
spleen size when compared
to wt littermate controls
(Fig. 4A; Fig. S4A). This
was due to decreased cellu-
larity, as both the number
of thymocytes and spleno-
cytes in v-cyclin animals
were significantly reduced
by 55–65% (Fig. 4B) and
45–60% (Fig. S4B),
respectively. As v-cyclin is
known to be a strong
inducer of the cell cycle,
proliferation22 as well as apoptosis,26,32,34 isolated thymocytes
were analyzed by FACS for proliferation and apoptosis. A moder-
ate, but significant, increase in proliferation (Ki67) and apoptosis
(Annexin V) was observed, suggesting an accelerated turnover of
thymocytes in v-cyclin mice (Fig. 4C and D). The cell cycle pro-
files (propidium iodide, PI) showed an increased proportion of
both sub-G1 and S-phase cells (Fig. 4E), reflecting increased apo-
ptosis and induction of an intra-S-phase block by v-cyclin. These
results suggest that v-cyclin elicits similar effects in T-cells in vivo
as seen previously in a variety of in vitro models.22,26,32
v-cyclin interferes with development of lymphocytes
The histological comparison of lymphoid organs revealed that
the spleens in the v-cyclin mice had a rather normal tissue archi-
tecture and similar numbers of B220 expressing B-cells as the
non-transgenic controls (Fig. S4C). However, the number of
CD3-positive T-lymphocytes was reduced both when analyzed
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Figure 3. Inhibition of the CDK4/6 activity induces cell death in Em-v-cyclin lymphomas and BCBL-1 cells. (A) Number
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by immunohistochemical staining (Fig. S4C) or by FACS using
an anti-CD3 antibody (Fig. S4D). To address the differentiation
state of T-cells, we performed multi-color FACS analysis of the
isolated splenic T lymphocytes using anti-CD4 and -CD8 anti-
bodies. This revealed that the numbers of mature T-cells, i.e.
CD4 single positive (CD4CCD8-) and CD8 single positive cells
(CD4-CD8C), were significantly diminished in the v-cyclin
expressing spleens (Fig. S4D).
We next assessed T-cell maturation in the thymus of v-cyclin
animals. Interestingly, histological stainings showed that the thy-
mic medullae, which normally contain mature T-cells, were
markedly smaller in v-cyclin mice (Fig. 5A, thymic medullae are
pointed by arrows). Fittingly, FACS analysis revealed a signifi-
cant reduction in the amount of CD3-positive cells in v-cyclin-
expressing thymi (65% in the wt vs. 50% in the v-cyclin,
Fig. 5B). Next, we analyzed the distribution of T-cell subpopula-
tions using anti-CD4 and -CD8 antibodies and FACS (Fig. 5C).
Among the v-cyclin thymocytes, the proportional numbers of
CD4-CD8-, CD4CCD8C and CD4-CD8C cells were
decreased, whereas the proportion of CD4CCD8- cells was
increased if compared to the distribution of CD4- and CD8-
expressing cells among the control thymocytes (Fig. 5C). Simul-
taneous analysis of Ki67 and AnnexinV expression by FACS
revealed that the extent of proliferation and apoptosis in these T-
cell subpopulations was otherwise similar to those in the whole
thymocyte population (Fig. 5C and D), except that the number
of Ki67 positive cells in the most immature, CD4-CD8- double
negative population was moderately but not significantly
decreased (Fig. 5D and E). When single positive CD4CCD8-
cells, whose relative amount was 2.8-fold- higher in the v-cyclin
expressing thymi over the control, were analyzed in conjunction
with anti-CD3, it appeared that they do not represent normal
CD4C T-helper cells as they lack the pan-T-cell marker CD3
expression (Fig. 5F). Since the thymic lymphomas showed an
interesting expression pattern of both T-cell markers and the
plasma cell and PEL marker CD138, we decided to study the
Figure 4. v-cyclin increases proliferation and apoptosis and induces an intra S-phase block in vivo. (A) Images of representative thymi from a littermate
control (wt) and an Em-v-cyclin (v-cyclin) mouse at 5 weeks of age. (B) The number of thymic cells counted from 2-week and 5-week old littermate
control (wt, n D 2 and n D 5, respectively) and Em-v-cyclin (v-cyclin, n D 6 and n D 8, respectively) mice. (C and D) Quantiﬁcation of a FACS analysis for
proliferation (Ki67 in (C)) and apoptosis (Annexin V in (D)) from the control (wt, n D 6) and v-cyclin (n D 5) thymocytes. Unstained thymocytes were used
as background controls. (E) Quantiﬁcation of a cell cycle analysis by FACS from PI-stained control (wt, n D 4) and v-cyclin (n D 6) thymocytes. Error bars
in (B–E): s.d. p-values: *P < 0.05, **P < 0.01, ***P< 0.001.
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Figure 5. v-cyclin expression alters the thymic morphology and interferes with T-cell differentiation. (A) Representative images of the H&E stained con-
trol (wt) and Em-v-cyclin (v-cyclin) thymi prior to the onset of lymphomagenesis. The thymic medullae are indicated by arrows. (B) Quantiﬁcation of FACS
analysis with anti-CD3 antibodies of the thymi from 5-week old littermate control (wt, n D 6) and Em-v-cyclin (v-cyclin, n D 4) mice. (C) The thymi in (B)
stained with combinations of anti-CD4 and -CD8 antibodies and analyzed by FACS (quantiﬁcations are shown). Unstained thymocytes were used as back-
ground controls. (D and E) FACS analysis of cells positive for Ki67 (D) and AnnexinV (E) in the CD4- and CD8-expressing thymocyte subpopulations in (C).
(F) Analysis of the CD3 status in the CD4CCD8C cells of the thymi in (B). Percentages of the CD3CCD4CCD8C and CD3highCCD4CCD8¡ cells, as well as
representative examples of the FACS plots are shown. (G) qRT-PCR analysis of CD138 mRNA levels in the pre-tumorigenic thymi of 5-week old littermate
control (wt, n D 4) and Em-v-cyclin (v-cyclin, n D 5) mice. Scale bars in (A): 200 mm. Error bars in (B): s.d.; in (C–E) and (G): s.e.m. p-values: *P < 0.05,
**P < 0.01, ***P < 0.001.
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expression of CD138 also in the pre-tumorigenic thymi. Interest-
ingly, an approximate ten-fold increase in the CD138 transcript
was detected in v-cyclin expressing thymi when compared to lit-
termate controls (Fig. 5G). These data suggest that v-cyclin
expression in thymus leads to a dramatic reduction of normal T-
cell populations, shifting to cell populations not normally found
in thymi at such high proportions.
Notch3 is induced in pre-tumorigenic thymi and thymic
lymphomas of Em-v-cyclin mice
To gain further insight into the mechanisms driving lympho-
magenesis in the ICR-Em-v-cyclin mice, we next addressed
expression of the Notch pathway components due to its well-
established role in T-cell development and lymphoma initia-
tion.42,43 Fittingly, a 3.4-fold increase of Notch3 receptor mRNA
levels was observed in pre-tumorigenic thymi of the v-cyclin
expressing animals as compared to the non-transgenic (wt) litter-
mates (Fig. 6A) along with a further 1.9-fold upregulation in the
thymic lymphomas (Fig. 6A). Notably, expression of Notch1
mRNA was found to be modestly but not significantly downre-
gulated in pre-tumorigenic organs of v-cyclin mice, but showed a
clear induction in the thymic lymphomas (Fig. 6A), suggesting
that its induction occurs at a later stage of lymphomagenesis. The
increase in Notch3 expression was also confirmed at the protein
level by immunostaining of thymus sections from these mice
(Fig. 6B). To investigate if Notch3 induction leads to pathway
activation, we analyzed the protein levels of the activated Notch3
intracellular domain (NICD3) and found it to be specifically
expressed in the v-cyclin expressing thymi (Fig. 6C) as well as in
3 out of 4 of the v-cyclin expressing lymphomas (Fig. 6C). In
accordance with this, one of the Notch downstream targets,
Hes1, was found to be significantly upregulated in the v-cyclin
expressing thymi (2.9-fold, Fig. 6D) and thymic lymphomas
(16.3-fold, Fig. 6D). Similar induction of another known Notch
target, Hey1, was detected in the pre-tumorigenic v-cyclin
expressing thymi, but the increase was not significant probably
due to intrinsically low expression levels in these samples
(Fig. 6D). Multiple tested Notch targets were not expressed at all
or expressed at very low levels in the pre-tumorigenic thymi
(Hey2 and Hes5, data not shown) or thymic lymphomas (Hey1,
Hey2 and Hes5, Figure 6D and data not shown). In line with the
Notch pathway activation, cyclin D3, another downstream target
of the Notch pathway, was found to be upregulated in the v-
cyclin expressing spleens and splenic lymphomas (Fig. 6E).
Notch3 transcription is regulated by CDK6
To gain more insight into the mechanism of v-cyclin-
mediated induction of Notch3, we tried to establish several sys-
tems with transient and inducible v-cyclin expression in a variety
of different cellular backgrounds. However, as v-cyclin has been
demonstrated to induce apoptosis, cell cycle arrest, DNA damage
and autophagy in a variety of cellular backgrounds,26,32-35 it
turned out to be challenging to establish a relevant and reliable
cell model to study the molecular mechanism of Notch3 induc-
tion in v-cyclin-expressing cells. Therefore, we decided to turn
our attention to the v-cyclin kinase partner CDK6 and assessed
the role of CDK6 in regulation of NOTCH3 transcription. To
this end, we silenced CDK6 in HEK293 cells by 2 different
shRNA constructs against CDK6. Silencing of CDK6 was effi-
cient (85% in HEK293 Fig. 6F) and led to a 70–80% inhibition
in NOTCH3 mRNA levels (Fig. 6F). This effect was specific for
NOTCH3 as there was no consistent effect on NOTCH1 mRNA
with these 2 constructs (Fig. 6F). In addition, CDK6 silencing
induced a significant downregulation of the Notch downstream
target HEY1 (Fig. 6F), and a minor effect on HES1, possibly
reflecting that it is regulated more by NOTCH1 (Fig. 6F). To
address if inhibition of NOTCH3 transcription was CDK6-spe-
cific we silenced CDK4, another G1 cell cycle regulating kinase.
Interestingly, efficient depletion of CDK4 expression (80%) had
no effect on NOTCH3 expression, thus suggesting that regula-
tion of NOTCH3 expression was specific for CDK6 (data not
shown). Next, we tested whether the kinase activity of CDK6
was needed for NOTCH3 transcription by treating the HEK293
cells with PD inhibitor. The inhibition led to 40% reduction in
NOTCH3 levels and significantly downregulated levels of the
Notch pathway targets HEY1 and HES, but CDK6 and
NOTCH1 levels were not affected (Fig. S5). This suggests that
the Notch pathway activation by CDK6 is kinase-dependent.
Em-v-cyclin lymphomas are dependent on active Notch
signaling
To assess if the activated Notch sustains growth and survival
of v-cyclin lymphoma cells, we treated the cells with 10 mM
gamma-secretase inhibitor DAPT for 72 hours. DAPT treatment
resulted in a growth arrest in all 3 Em-v-cyclin thymic lymphoma
lines examined (see a representative graph in Fig. 7A), but had
no effect on growth of the control Em-Myc thymic lymphoma
cells (example graph in Fig. 7B). DAPT also significantly
increased cell death of v-cyclin lymphoma cells at 48 h (Fig. 7C)
as indicated by a 25–55% increase in the number of dead cells
when compared to vehicle treated cells. Similar results were
obtained with lymphoma lines isolated from the spleens and
lymph nodes (Fig. 7C). DAPT treatment of the v-cyc1 lym-
phoma cells with initial high expression levels of the activated
NICD3 and NICD1, led to a 20–54% and 80–90% reduction
in their expression, respectively (Fig. 7D). The inhibitory effect
of DAPT on generation of NICD3 and NICD1 was less evident
in the other lymphoma cell lines probably due to lower protein
expression levels of the Notch receptors (Fig. 7D). To further
prove the efficacy of the inhibitor we perfomed qRT-PCR analy-
sis which showed 50–90% inhibition of the Notch1 downstream
target Hes1 mRNA after the DAPT treatment (Fig. 7E). These
data suggest that growth and viability of Em-v-cyclin lymphomas
are dependent on activation of the Notch pathway.
Discussion
T-cell development and lymphomagenesis are closely linked,
and aberrations in the carefully regulated molecular events of T-
cell differentiation can trigger T-cell lymphomagenesis. For
example, expression of oncogenes at specific differentiation stages
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leads to developmental arrest and accumulation of immature T-
lymphocytes.42,44 In our mouse model, v-cyclin functions as an
oncogene in the T-cells, leading to defects in their maturation
and initiating early-onset T-cell lymphoma and T-cell
autoimmunity. It is somewhat surprising that the v-cyclin mice
have defects in thymic development and T-cells, although v-
cyclin expression levels are dramatically lower in thymocytes than
splenocytes. This suggests that v-cyclin expression targets
Figure 6. Notch signaling is induced in v-cyclin expressing pre-tumorigenic thymi and lymphomas. (A) Notch3 and Notch1mRNA expression levels in the
pre-tumorigenic thymi of 5-week old littermate control (wt, n D 5) and Em-v-cyclin (v-cyclin, n D 5) mice, and in Em-v-cyclin thymic lymphomas (n D 3).
(B) Immunohistochemistry with anti-Notch3 antibody (red) and counterstained with Hoechst (blue) of the thymi in (A). Sections stained without the pri-
mary antibody (1Ab omitted) were used as a control. (C) Immunoblotting with antibodies against NICD3 from cell extracts prepared from pre-
tumorigenic thymi of control (wt, n D 4) and Em-v-cyclin (v-cyclin, n D 4) mice, and from Em-v-cyclin thymic lymphomas (n D 4). g-tubulin served as a
loading control. (D) Notch pathway target Hes1 and Notch1mRNA expression levels in the thymi in (A). (E) The membrane analyzed inFigure 2C was fur-
ther immunoblotted with anti-cyclin D3 antibodies and the expression levels were analyzed in splenocytes of Em-v-cyclin (v-cyc) and control mice (wt),
as well as lymphoma cells isolated from the v-cyclin spleens. Quantiﬁcation of the signal normalized to g-tubulin is shown in the lower panel. (F) qRT-
PCR analysis of CDK6, NOTCH3, NOTCH1, HEY1, and HES1 in 293HEK cells transduced with lentiviruses expressing scrambled shRNA (scr) or 2 different
shCDK6 (sh-CDK6_1 and sh-CDK6_2). Error bars in (A) and (D–F): s.e.m., n D 2–4. p-values: *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 7. Em-v-cyclin lymphoma cells are dependent on Notch signaling. (A) Number of live cells in a representative Em-v-cyclin lymphoma cell line left
untreated (mock), or treated with a vehicle control (EtOH) or 10 mM DAPT for 3 d (d0–d3). (B) Number of live cells in control Em-Myc lymphoma cells
treated as in (A). (C) Cell death in Em-v-cyclin lymphoma cell lines (v-cyc1, v-cyc2, v-cyc3) and in a control Em-Myc cell line (Em-Myc), all treated with
10mM DAPT for 2 d. Dead cells in the corresponding vehicle (EtOH) treated samples are subtracted from the DAPT-treated samples as a background.
LN D lymph node. (D) Immunoblotting using anti-NICD3 and -NICD1 antibodies from extracts prepared from Em-v-cyclin lymphoma cell lines (v-cyc1,
v-cyc2, v-cyc3) treated as in (C). Quantiﬁcations of the signals are shown under blots and are normalized to g-tubulin, which serves as a loading control.
T D thymus, S D spleen, LN D lymph node. (E) Hes1 mRNA levels analyzed by qRT-PCR in Em-v-cyclin lymphoma lines (v-cyc1, v-cyc2, v-cyc3) and in the
control Em-Myc lymphoma line after vehicle (EtOH) or 10 mM DAPT treatment for one day. Expression levels are normalized to vehicle-treated Em-v-cyclin
thymic lymphoma cells (v-cyc1). T D thymus, S D spleen, LN D lymph node. Scale bars in (B): 50 mm. Error bars in (C) and (E): s.e.m., n D 3. p-values:
*P < 0.05, **P < 0.01, ***P < 0.001.
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molecules and pathways that are particularly important for the
development of T-lymphocytes and T-cell lymphoma. These are
likely mediated through activation of the v-cyclin cellular kinase
partner CDK6. CDK6 is known to be highly active in T-cells
and important for the orderly development of the thymus,45-47
and of its cellular cyclin partners cyclin D3 shares unique func-
tions in lymphocyte development.48 Moreover, CDK6 expres-
sion levels are often increased in T-cell lymphomas,49 and cyclin
D3-CDK6 activity has been shown to be essential for T-cell lym-
phomas.48 Fittingly, we see in this mouse model that v-cyclin
expression in T-lymphocytes elevates both the Cdk6 and cyclin
D3 expression levels and they are further upregulated in the lym-
phomas (Fig. 2C, 6E, S2A, S2B and ref.39). As the v-cyclin
expression levels are low at the lymphoma stage, it is possible that
v-cyclin initiates the changes that affect the cellular targets and
pathways important for T-cell development and lymphoma, but
it is the elevated cyclin D3-CDK6 that is responsible for the pro-
liferation and growth of the lymphomas.
Importantly, we show here that inhibition of CDK6 activity
induces cell death in the Em-v-cyclin lymphoma cells and BCBL-
1 PEL cells, suggesting that growth and viability of both lym-
phoma types are dependent on CDK6 activity. Appropriately,
CDK4/6 inhibition has shown promising results in therapeutic
targeting of both B- and T-cell lymphomas,48,50 and CDK4/6
inhibitors are now in phase III clinical trials for estrogen receptor
(ER)-positive breast cancer and chronic lymphocytic leuke-
mia.50,51 This implies that new generation CDK4/6 inhibitors
may provide significant therapeutic potential in the near future,
and our data suggests that testing these inhibitors in KSHV-posi-
tive patients with PELs may improve prognosis of this currently
incurable disease.
Besides Cdk6, the Notch signaling pathway plays a critical
role in T-cell development.43 This is the first study to describe
that KSHV v-cyclin expression activates Notch signaling through
induction of Notch3 and Hes1 (Figs. 6 and 7). Notch signaling is
a tightly regulated process with a recognized role in the initiation
of T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).42,52
Several studies have confirmed that Notch is an important regula-
tor of haematopoietic progenitor commitment to the T-cell line-
age, and is involved in the DN to DP transition.42 Activating
mutations of NOTCH1 are found in more than 50% of the
human T-ALL cases,53 and several knock in/out animal models
support its importance in T-ALL.42 In addition, transgenic mice
expressing the constitutively active Notch3 intracellular domain
NICD3 have been shown to develop T-cell lymphomas,54,55
indicating that also Notch3 activation can potentially initiate T-
cell lymphoma. Therefore, the increased expression of Notch3, its
intracellular activated form NICD3, and the Notch pathway tar-
gets Hes1, Hey1 and cyclin D3 are likely to play a role in the
abnormal T-cell development and initiation of lymphomas in
the Em-v-cyclin mice. Notably, these T-cell lymphomas are best
classified as T-cell lymphoblastic lymphoma, a cancer of imma-
ture T-cells highly related to T-ALL. We further demonstrate
that Notch3 transcription is dependent on CDK6 expression.
Previous studies have established D-type cyclins as downstream
effectors of Notch in lymphomagenesis.56-58 Our work here
reveals a cyclin-CDK complex as an upstream regulator of Notch
receptor transcription, suggesting that also cellular cyclins may
not only function as effectors but also have a role in the initiation
of Notch-dependent lymphomagenesis.
Besides T-cell lymphoma, Notch signaling reportedly plays an
important role in the pathogenesis of KSHV-associated malignan-
cies.12 Several Notch pathway components, including the Notch
receptors themselves, are upregulated in KS.13 However, the viral
factors inducing the Notch receptors have remained mostly
unknown. Here we identify v-cyclin as an additional KSHV viral
protein engaging the Notch pathway through induction of a
Notch receptor. Importantly, this renders v-cyclin-expressing lym-
phomatous T-cells dependent on the Notch activity, as chemical
inhibition of the pathway resulted in cell death of v-cyclin-driven
lymphoma cells. Our study thus reveals new insights in KSHV
pathogenesis by linking expression of a viral oncogene to Notch
pathway activation, and further supports the earlier reports show-
ing that inhibition of Notch might serve as a good strategy in treat-
ing KSHV-induced malignancies.13,16,18,19
It is clear that this mouse model, in which v-cyclin is expressed
in isolation of the other viral factors, only covers a small subset of
all v-cyclin functions. Yet, this study reveals that v-cyclin expres-
sion in vivo not only recapitulates several of its properties identi-
fied in cell culture models, but also provides novel insights into
KS/PEL pathogenesis. Our data shows that, in an appropriate
cellular context, v-cyclin can act as a true oncogene, giving rise to
lymphoma when expressed even at low expression levels, without
a requirement for additional initiator mutations in the common
tumor suppressors. This is especially important as v-cyclin is a
latent KSHV gene and, in contrast to the majority of the KSHV
genes, expressed constitutively during the viral infection. In
addition, here we show for the first time that KSHV v-cyclin
modulates the Notch pathway via receptor up-regulation, and
demonstrate that v-cyclin expression leads to dysregulated organ
development due to inhibition of normal T lymphocyte matura-
tion. Moreover, we report an abnormal induction of the plasma
cell/ PEL marker CD138 in the v-cyclin-expressing pre-tumori-
genic thymi and lymphomas, which resembles the aberrant
T-cell phenotype of some rare cases of PELs.7,8 Lastly, we also
demonstrate that growth of these lymphomas can be inhibited
with compounds blocking Notch or Cdk4/6, implying that
simultaneous inhibition of these 2 targets could improve the cur-
rently poor therapeutic outcome of advanced PEL, and perhaps
also KS.
Materials and Methods
Em-v-cyclin transgenic mice and isolation of mouse
lymphocytes
The Em-v-cyclin transgenic mouse strain is previously
described in refs.33,36 These mice were bred into the outbred
ICR (CD1) mouse background for at least 5 generations (ICR-
Em-v-cyclin) or backcrossed to the inbred C57BL6 background
for at least 5 generations (BL6- Em-v-cyclin), and maintained as
described earlier.33,36 Em-Myc mice were generated and
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maintained as previously described.59 All mouse experiments
were approved by Finnish National Animal Experiment Board
(license numbers: ESLH-2005–03350/Ym-23, ESLH-2006–
04075/Ym-23, ESLH-2009–02139/Ym-23). Thymi and spleens
from 2- or 5.5-week old pre-tumorigenic Em-v-cyclin mice as
well as tumors from lymphoma bearing mice were obtained from
the sacrificed mice by dissection. Tissue was disaggregated by
pressing through a 70-mm nylon mesh cell strainer (BD Falcon)
in RPMI containing 10% FCS to obtain a single cell suspension.
Splenic erythrocytes were eliminated by incubation for 5 min at
room temperature in ACK buffer (155 mM NH4Cl, 10 mM
KHCO3, and 0.1 mM EDTA, pH 7.8). Thymic and splenic
lymphocytes and lymphoma cells were pelleted and washed once
with PBS before further use for FACS as well as RNA lysates.
Lymphoma cells used for cell culture were frozen (1 £ 107 cells/
vial) or cultured in lymphoma medium described in.60
Cell lines
Lymphoma cell lines isolated from Em-v-cyclin/ICR mice, as
well as control Em-Myc thymic lymphoma cultured in lym-
phoma medium were propagated every second to fourth day,
kept at cell density between 2 £ 105 to 107 cells/ml and
grown for at least 3 passages before further analysis. The BCBL-1
(NIH AIDS Reagent Program, catalog number 3233 from
McGrath and Ganem) cells,61 as wells as HEK293FT (obtained
from Biomedicum Functional Genomics Unit, FuGU),
HEK293A (a kind gift from Dr. V€ah€a-Koskela) and 293HEK-
FlipIn cells (Invitrogen) were cultured as described previously.27
All cells were cultured in a humidified 5% CO2 atmosphere at
37C.
Lentivirus production and transductions
Lentiviral constructs containing scrambled shRNA (sh-scr:
SHC005) and 2 different shCDK6s (sh-CDK6_1:
TRCN0000039747, sh-CDK_2: TRCN0000194893) in
pLKO.1 vector backbone were obtained from Biomedicum
Functional Genomics Unit (FuGU) and the viruses were pro-
duced in HEK293FT cells as previously described.32 The
HEK293A and HEK293-FlipIn cells were transduced with con-
centrated viruses as described in.32 The cell pellets for qRT-PCR
analysis were collected 48 h after transductions.
Antibodies
In western blotting and immunoprecipitations following anti-
bodies were used: FLAG (M2, Sigma), Cdk2 (sc-163, Santa
Cruz), Cdk4 (sc-601, Santa Cruz), Cdk6 (#MS-451, Thermo
Scientific), v-cyclin,27 Cdk6 (C-21, Santa Cruz), CD3 (A0452,
Dako), Cyclin D3 (sc-182, Santa Cruz), g-tubulin (GTU-88,
Sigma), Cyclin A (sc-596, Santa Cruz), (phosphoT199-NPM
(Cell Signaling, #3541), NPM (32–5200, Invitrogen), NICD1
(ab8925, Abcam), NICD3 (sc-7424, Santa Cruz). Antibodies
against CD3 (A0452, Dako), B220 (RA3-6B2, SouthernBiotech)
and Notch3 (N5038, Sigma) were used to stain tissue sections.
For FACS, pre-conjugated antibodies (all from BD PharMingen)
against CD4 (PE, H129.9), CD8 (FITC, 53-5.8), CD3 (PE-
Cy7, 145-2C11) and Ki-67 (PerCP-Cy5.5, B56) or Annexin V
(APC) were used.
In vitro kinase reaction, immunoprecipitation and protein
gel blotting
For immunoprecipitations, and their whole-cell lysate con-
trols, cells were lysed in an ELB lysis buffer (50 mM Hepes (pH
7.4), 150 mM NaCl; 50 mM HEPES, pH 7.4; 0.1% Igepal;
5 mM EDTA; 2 mM DTT; 1 mM phenylmethylsulfonyl fluo-
ride [PMSF]; 2 mg/mL leupeptin; 2 mg/mL pepstatin; and
1.5 mg/mL aprotinin). For immunoprecipitations 300–1000 mg
of protein were used per sample. Immunodepletions were per-
formed using antibodies against Cdk2, Cdk4 and Cdk6 followed
by the immunoprecipitation against v-cyclin by using antibodies
against v-cyclin or FLAG and in vitro kinase reaction by using
GST-Rb and Histone H1 as substrates as described previously.27
40 mg-75 mg of the cleared whole-cell extracts were analyzed by
western blotting as described previously.27 Antibody binding was
visualized by enhanced chemiluminescence (ECL, Femto from
Pierce or Sirius from Advansta).
Inhibitor assays
Mouse lymphoma cells and PEL cells at a starting density of
1–2 £ 105 cells/ml were incubated for 72 h with DAPT
(10 mM; Sigma) or PD0332991 (0.5–1 mM; Adooq Bioscience)
or corresponding vehicle control (EtOH/DMSO). The number
of live and dead cells were determined by trypan blue exclusion
and counting with a TC10 Automated cell counter (Bio-rad) at
0 h, 24 h, 48 h and 72 h after adding the inhibitor. Cell pellets
for analysis by real time quantitative PCR were collected at 24 h
or 48 h and for WB analysis at 48 h.
Real time quantitative PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen) or
the NucleoSpin RNA II kit (Macherey Nagel). Transcript levels were
measured by qRT-PCR using Taqman Gene Expression Assays
(Applied Biosystems) with the following FAM-labeled primers for
Notch3 (Mm00435270_m1), Hes1 (Mm01342805_m1), Hey1
(Mm00468865_m1), Gapdh (Mm03302249_g1), HEY1
(Hs00232618_m1) HES1 (Hs00172878_m1) or GAPDH
(Hs03929097_g1) (Applied Biosystems) in the StepOnePlus Real
Time PCR system (Applied Biosystems) or in the Lightcycler 480
(Roche). For unlabeled primers, reactions were done using the SYBR
Green PCR mix (Fermentas) and QuantiTect Primer Assay against
NOTCH3 (QT00003374, Qiagen) or the following primer sequen-
ces (forward and reverse):
v-cyclin: CGGACGTCACTTCCTTCTTG and
CGCAGATCAAAGTCCGAAAC
Notch1: CCGTGTAAGAATGCTGGAACG
and AGCGACAGATGTATGAAGACTCA
Gapdh: TCAACGACCCCTTCATTGAC
and ATGCAGGGATGATGTTCTGG
CDK6: CCAGATGGCTCTAACCTCAGT
and AACTTCCACGAAAAAGAGGCTT
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NOTCH1:GAGGCGTGGCAGACTATCATGC
and CTTGTACTCCGTCAGCGTGA
GAPDH: TCACCACCATGGAGAAGGCT
and GCCATCCACAGTCTTCTGGG
The data was normalized to expression of the Gapdh/GAPDH
cellular housekeeping gene.
Statistical analysis
For statistical analysis of the qRT-PCR data logarithmic
values were converted to ddCt values (linear log2 scale values)
and p values were calculated with a one-tailed unpaired
Student’s t test. The p values for FACS data were calculated
directly from the data normalized to the appropriate control.
*P < 0.05, **P < 0.01, ***P < 0.001.
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